An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers

Anna Murphy, Serdar Dursun, Shane McKie, Rebecca Elliott, John F. W. Deakin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Rationale
Working memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D2 receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D2 receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory.

Objectives
We probed the implications of the partial D2 receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D2/5-HT2A blocker risperidone to separate aripiprazole’s unique prefrontal D2 agonist actions from its serotinergic and striatal D2 actions that it shares with risperidone.

Method
A double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning.

Results
Compared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo.

Conclusion
Aripiprazole has unique DLPFC actions attributed to its prefrontal D2 agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D2 blockade.
Original languageEnglish
Pages (from-to)1415-1426
Number of pages12
JournalPsychopharmacology
Volume233
Issue number8
Early online date22 Feb 2016
DOIs
Publication statusPublished - Apr 2016
Externally publishedYes

Fingerprint

Prefrontal Cortex
Short-Term Memory
Risperidone
Healthy Volunteers
Placebos
Dopamine
Corpus Striatum
Aripiprazole
Antipsychotic Agents
Reaction Time
Schizophrenia
Magnetic Resonance Imaging

Cite this

Murphy, Anna ; Dursun, Serdar ; McKie, Shane ; Elliott, Rebecca ; Deakin, John F. W. / An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. In: Psychopharmacology. 2016 ; Vol. 233, No. 8. pp. 1415-1426.
@article{dcd1554eb0364823bde287b4c9b2c716,
title = "An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers",
abstract = "RationaleWorking memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D2 receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D2 receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory.ObjectivesWe probed the implications of the partial D2 receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D2/5-HT2A blocker risperidone to separate aripiprazole’s unique prefrontal D2 agonist actions from its serotinergic and striatal D2 actions that it shares with risperidone.MethodA double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning.ResultsCompared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo.ConclusionAripiprazole has unique DLPFC actions attributed to its prefrontal D2 agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D2 blockade.",
keywords = "Antipsychotic, Aripiprazole, D2, Dopamine, Dorsolateral prefrontal, n-Back, Partial agonism, Risperidone, Working memory",
author = "Anna Murphy and Serdar Dursun and Shane McKie and Rebecca Elliott and Deakin, {John F. W.}",
note = "Cited by 2",
year = "2016",
month = "4",
doi = "10.1007/s00213-016-4234-9",
language = "English",
volume = "233",
pages = "1415--1426",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "8",

}

An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. / Murphy, Anna; Dursun, Serdar; McKie, Shane; Elliott, Rebecca; Deakin, John F. W.

In: Psychopharmacology, Vol. 233, No. 8, 04.2016, p. 1415-1426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers

AU - Murphy, Anna

AU - Dursun, Serdar

AU - McKie, Shane

AU - Elliott, Rebecca

AU - Deakin, John F. W.

N1 - Cited by 2

PY - 2016/4

Y1 - 2016/4

N2 - RationaleWorking memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D2 receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D2 receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory.ObjectivesWe probed the implications of the partial D2 receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D2/5-HT2A blocker risperidone to separate aripiprazole’s unique prefrontal D2 agonist actions from its serotinergic and striatal D2 actions that it shares with risperidone.MethodA double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning.ResultsCompared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo.ConclusionAripiprazole has unique DLPFC actions attributed to its prefrontal D2 agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D2 blockade.

AB - RationaleWorking memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D2 receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D2 receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory.ObjectivesWe probed the implications of the partial D2 receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D2/5-HT2A blocker risperidone to separate aripiprazole’s unique prefrontal D2 agonist actions from its serotinergic and striatal D2 actions that it shares with risperidone.MethodA double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning.ResultsCompared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo.ConclusionAripiprazole has unique DLPFC actions attributed to its prefrontal D2 agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D2 blockade.

KW - Antipsychotic

KW - Aripiprazole

KW - D2

KW - Dopamine

KW - Dorsolateral prefrontal

KW - n-Back

KW - Partial agonism

KW - Risperidone

KW - Working memory

UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958748955&doi=10.1007%2fs00213-016-4234-9&partnerID=40&md5=9ecc16f4bb643a6fcb65c8dc7041f9a1

U2 - 10.1007/s00213-016-4234-9

DO - 10.1007/s00213-016-4234-9

M3 - Article

VL - 233

SP - 1415

EP - 1426

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 8

ER -